Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
Cellini A, Salvalaggio A, Velasco R, Arnan M, Cacciavillani M, Riva M, Trentin L, Pomares H, Lessi F, Briani C. Cellini A, et al. Among authors: arnan m. Leuk Lymphoma. 2024 Dec;65(13):2060-2063. doi: 10.1080/10428194.2024.2391899. Epub 2024 Aug 13. Leuk Lymphoma. 2024. PMID: 39138968 No abstract available.
Targeting prohibitins induces apoptosis in acute myeloid leukemia cells.
Pomares H, Palmeri CM, Iglesias-Serret D, Moncunill-Massaguer C, Saura-Esteller J, Núñez-Vázquez S, Gamundi E, Arnan M, Preciado S, Albericio F, Lavilla R, Pons G, González-Barca EM, Cosialls AM, Gil J. Pomares H, et al. Among authors: arnan m. Oncotarget. 2016 Oct 4;7(40):64987-65000. doi: 10.18632/oncotarget.11333. Oncotarget. 2016. PMID: 27542247 Free PMC article.
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group. Nomdedeu M, et al. Among authors: arnan m. Leuk Res. 2017 Dec;63:85-89. doi: 10.1016/j.leukres.2017.10.011. Epub 2017 Oct 28. Leuk Res. 2017. PMID: 29121539
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Montoro J, Pomares H, Villacampa G, Merchán B, Molero A, Alonso E, Gallur L, Grau J, Salamero O, Roldán E, Saumell S, Ortega M, Sureda A, Bosch F, Arnan M, Valcárcel D. Montoro J, et al. Among authors: arnan m. Leuk Lymphoma. 2019 Jun;60(6):1522-1527. doi: 10.1080/10428194.2018.1542151. Epub 2018 Nov 30. Leuk Lymphoma. 2019. PMID: 30499738
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.
Condom M, Mussetti A, Maluquer C, Parody R, González-Barca E, Arnan M, Albasanz-Puig A, Pomares H, Salas MQ, Carro I, Peña M, Clapes V, Baca Cano C, Oliveira Ramos AC, Sanz-Linares G, Moreno-González G, Mercadal S, Boqué C, Gudiol C, Domingo-Domènech E, Sureda A. Condom M, et al. Among authors: arnan m. Cancer Rep (Hoboken). 2021 Aug;4(4):e1358. doi: 10.1002/cnr2.1358. Epub 2021 Mar 3. Cancer Rep (Hoboken). 2021. PMID: 33656801 Free PMC article.
B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.
Arribas I, Maluquer C, Pomares H, Carro I, Baca C, Bosch A, Arévalo CE, Montané C, Ribes-Amorós J, Zamora L, Granada I, Gamundi E, Arnan M, Sureda A. Arribas I, et al. Among authors: arnan m. Leuk Lymphoma. 2023 Oct;64(10):1701-1705. doi: 10.1080/10428194.2023.2234527. Epub 2023 Jul 17. Leuk Lymphoma. 2023. PMID: 37455651 Review. No abstract available.
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Jiménez-Vicente C, Martínez-Roca A, Pomares H, Castaño-Diez S, Guijarro F, López-Guerra M, Bataller A, Esteban D, Cortés-Bullich A, Pérez-Valencia AI, Guardia-Torrelles A, Zugasti I, Rovira M, Fernández-Avilés F, Colomer D, Arnan M, Díaz-Beyá M, Esteve J. Jiménez-Vicente C, et al. Among authors: arnan m. Leuk Res. 2023 Dec;135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30. Leuk Res. 2023. PMID: 37837718 No abstract available.
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Castaño-Díez S, Pomares H, Esteban D, Guijarro F, Jiménez-Vicente C, Zugasti I, Álamo JR, Mayayo VT, López-Guerra M, de la Fuente C, Charry P, Cortés-Bullich A, Bataller Á, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: arnan m. Br J Haematol. 2024 Mar;204(3):892-897. doi: 10.1111/bjh.19217. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38013238
99 results